MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Sep 3, 04:54 PM (EDT)
Price
$30.30
Change
+$0.16 (+0.53%)
Net Assets
49.84M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Sep 02, 2025

Momentum Indicator for HRTS turns positive, indicating new upward trend

HRTS saw its Momentum Indicator move above the 0 level on August 13, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned positive. In of the 23 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for HRTS just turned positive on August 14, 2025. Looking at past instances where HRTS's MACD turned positive, the stock continued to rise in of 20 cases over the following month. The odds of a continued upward trend are .

HRTS moved above its 50-day moving average on August 13, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for HRTS crossed bullishly above the 50-day moving average on August 21, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 5 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 109 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

HRTS broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HRTS entered a downward trend on August 15, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NASDAQ:AZN), Abbott Laboratories (NYSE:ABT), Merck & Co (NYSE:MRK), Boston Scientific Corp (NYSE:BSX), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 86.55B. The market cap for tickers in the group ranges from 3.51M to 661.43B. LLY holds the highest valuation in this group at 661.43B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 92%. For the same ETF, the average monthly price growth was 124%, and the average quarterly price growth was 178%. IONS experienced the highest price growth at 36%, while AKRO experienced the biggest fall at -6%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was 12%. For the same stocks of the ETF, the average monthly volume growth was -5% and the average quarterly volume growth was 19%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 53
P/E Growth Rating: 72
Price Growth Rating: 51
SMR Rating: 72
Profit Risk Rating: 69
Seasonality Score: -35 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co